Vulnerability of the mosquito larvae to the guppies (Poecilia reticulata) in the presence of alternative preys

Background & objectives: The predatory potential of the larvivorous fishes can be affected by the presence of alternative preys. In the present study the predation pattern of the sewage dwelling Poecilia reticulata (Peters 1872) on the larvae of Culex quinquefasciatus Say 1823 (Diptera: Culicidae) was evaluated in the presence of alternative preys. Methods: The predation of Cx. quinquefasciatus larvae by different size groups of P. reticulata fishes was evaluated. In addition to this, the niche breadth (N) and diet breadth (B) were measured following Manly’s selectivity index (Si) as an indicator of variation of such predation pattern in the presence of alternative prey types, like chironomid larvae and tubificid worms.Results: The consumption of IV instar Cx. quinquefasciatus larvae by individual P. reticulata ranged between 65 and 84 in a 3 h feeding period and varied with the size of fish (F2, 33 = 34.91; p<0.001). The selectivity coefficient revealed a significantly low preference for the Cx. quinquefasciatus larvae (0.16, CL: 0.05 – 0.27; p< 0.05) compared to the chironomid larvae and tubificid worms, when all the three prey types were present. The niche breadth (N) and diet breadth (B) ranged from 0.77 to 0.92 and 0.69 to 0.93, respectively. The total consumption of all the prey types varied with the predator density, but the selectivity index for the mosquito larvae was significantly low in all the instances.Interpretation & conclusion: P. reticulata can consume a good number of mosquito larvae, with the consumption rate varying with the body size. P. reticulata fishes exhibit low preference for mosquito larvae as prey in the presence of alternative controphic preys like chironomid larvae and tubificid worms. Though establishment and sustenance of P. reticulata in new habitats will be favoured by the presence of alternative preys, but vulnerability of mosquito larvae may be reduced with availability of multiple preys in natural conditions

High-Resolution Genotyping of the Endemic Salmonella Typhi Population during a Vi (Typhoid) Vaccination Trial in Kolkata

Typhoid fever is caused by the bacterium Salmonella enterica serovar Typhi (S. Typhi) and is a major health problem especially in developing countries. Vaccines against typhoid are commonly used by travelers but less so by residents of endemic areas. We used single nucleotide polymorphism (SNP) typing to investigate the population structure of 372 S. Typhi bacteria isolated from typhoid patients during a typhoid disease burden study and Vi anti-typhoid vaccine trial in Kolkata, India. Approximately sixty thousand people were enrolled for fever surveillance for 19 months prior to, and 24 months following, vaccination of one third of the study population against typhoid (May 2003–December 2006, vaccinations given December 2004). We detected a diverse population of S. Typhi, including 21 different genetic forms (haplotypes) of the bacteria. The most common (69%) were of a haplogroup known as H58, which included all multidrug resistant isolates (bacteria resistant to the antibiotics chloramphenicol, ampicillin and co-trimoxazole). Resistance to quinolones, a class of antibiotics commonly used to treat typhoid fever, was particularly high among a subgroup of H58 (H58-G). Vi vaccination did not obviously impact on the haplotype distribution of the S. Typhi circulating during the study period

Spirocyclopentene Oxindoles through LiHMDS Based Allylation and Ring Closing Metathesis

Spirocyclopentene Oxindoles through LiHMDS Based Allylation and Ring Closing Metathesi

Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India.

INTRODUCTION:Atorvastatin-80mg/day and Rosuvastatin-40mg/day are the commonest high-dose statin (3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors) regimes for post-PCI (Percutaneous Coronary Interventions) patients to lower (by ≥50%) blood low-density-lipoprotein cholesterol (LDL-C). Dearth of conclusive evidence from developing world, regarding overall safety, tolerability and comparative effectiveness (outcome/safety/tolerability/endothelial inflammation control) of Rosuvastatin over Atorvastatin in high-dose, given its higher cost, called for an overall and comparative assessment among post-PCI patients in a tertiary cardiac-care hospital of Kolkata, India. METHODS:A record-based non-concurrent cohort study was conducted involving 942 post-PCI patients, aged 18-75 years, on high-dose statin for three months and followed up for ≥one year. Those on Atorvastatin-80mg (n = 321) and Rosuvastatin-40mg (n = 621) were compared regarding outcome (death/non-fatal myocardial infarction: MI/repeated hospitalization/target-vessel revascularisation/control of LDL and high-sensitivity C-reactive protein: hsCRP), safety (transaminitis/myopathy/myalgia/myositis/rhabdomyolysis), tolerability (gastroesophageal reflux disease: GERD/gastritis) and inflammation control adjusting for socio-demographics, tobacco-use, medications and comorbidities using SAS-9.4. RESULTS:Groups varied minimally regarding distribution of age/gender/tobacco-use/medication/comorbidity/baseline (pre-PCI) LDL and hs-CRP level. During one-year post-PCI follow up, none died. One acute MI and two target vessel revascularizations occurred per group. Repeated hospitalization for angina/stroke was 2.18% in Atorvastatin group vs. 2.90% in Rosuvastatin group. At three-months follow up, GERD/Gastritis (2.18% vs 4.83%), uncontrolled hs-CRP (22.74% vs 31.08%) and overall non-tolerability (4.67% vs. 8.21%) were lower for Atorvastatin group. Multiple logistic regression did show that compared to Atorvastatin-80mg, Rosuvastatin-40mg regime had poorer control of hs-CRP (A3OR = 1.45,p = 0.0202), higher (A3OR = 2.07) adverse effects, poorer safety profile (A3OR = 1.23), higher GERD/Gastritis (A3OR = 1.50) and poorer overall tolerability (A3OR = 1.50). CONCLUSION:Post-PCI high dose statins were effective, safe and well-tolerated. High dose Rosuvastatin as compared to high dose Atorvastatin were similar in their clinical efficacy. Patients treated with Atrovastatin had significantly lower number of patients with hs-CRP (high-sensitivity C-reactive protein)/C-reactive protein (CRP) level beyond comparable safe limit and relatively better tolerated as opposed to Rosuvastatin-40mg.Thus given the lower price, Atorvastatin 80mg/day appeared to be more cost-effective. A head-to-head cost-effectiveness as well as efficacy trial may be the need of the hour

Predictors of rational management of diarrhea in an endemic setting: observation from India.

Decades after the establishment of clear guidelines for management, mostly due to irrational approach, diarrhea is still a major concern in the developing world, including India. The scenario is even worse in urban slums owing to poor health-seeking and socio-environmental vulnerability. Determining the distribution of rational diarrhea management by practitioners and identification of its important predictors seemed urgent to minimize the potential for antibiotic resistance, diarrhea-related mortality and morbidity in these areas.Between May 2011 and January 2012, 264 consenting, randomly selected qualified and non-qualified practitioners (including pharmacists) were interviewed in the slums of Kolkata, a populous city in eastern India, regarding their characteristics, diarrhea-related knowledge (overall and in six separate domains: signs/symptoms, occurrence/spread, management, prevention/control, cholera and ORS), prescribed antibiotics, intravenous fluid (IVF) and laboratory investigations. Rationality was established based on standard textbooks.Among participants, 53.03% had no medical qualifications, 6.06% were attached to Governmental hospitals, 19.32% had best knowledge regarding diarrhea. While treating diarrhea, 7.20%, 17.80% and 20.08% respectively advised antibiotics, IVF and laboratory tests rationally. Logistic regression revealed that qualified and Governmental-sector practitioners managed diarrhea more rationally. Having best diarrhea-related knowledge regarding signs/symptoms (OR=5.49, p value=0.020), occurrence/spread (OR=3.26, p value=0.035) and overall (OR=6.82, p value=0.006) were associated with rational antibiotic prescription. Rational IVF administration was associated with best knowledge regarding diarrheal signs/symptoms (OR=3.00, p value=0.017), occurrence/spread (OR=3.57, p value=0.004), prevention/control (OR=4.89, p value=0.037), ORS (OR=2.55, p value=0.029) and overall (OR=4.57, p value<0.001). Best overall (OR=2.68, p value=0.020) and cholera-related knowledge (OR=2.34, p value=0.019) were associated with rational laboratory testing strategy.Diarrheal management practices were unsatisfactory in urban slums where practitioners' knowledge was a strong predictor for rational management. Interventions targeting non-qualified, independent practitioners to improve their diarrhea-related knowledge seemed to be required urgently to ensure efficient management of diarrhea in these endemic settings

An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India.

BACKGROUND:The bivalent killed oral cholera vaccine (OCV) provides 65% cumulative protection over five years. It remains unknown whether a boosting regimen can maintain protection in previously immunized populations. This study examines the immunogenicity and safety of an OCV regimen given five years following initial dosing. METHODOLOGY/PRINCIPAL FINDINGS:An open label controlled trial was conducted in 426 healthy Indian participants previously enrolled in a large efficacy trial. To assess whether an OCV regimen given after five years can elicit an antibody response equal to that of a primary series, we compared vibriocidal antibody titers in previously immunized participants receiving a two dose booster regimen to participants receiving a primary two dose immunization series. Among participants receiving a two dose primary series of OCV (n = 186), 69% (95% CI 62%-76%) seroconverted. In the intervention arm (n = 184), 66% (95% CI 59%-73%) seroconverted following a two dose boosting schedule given five years following the initial series. Following a single boosting dose, 71% (95% CI 64%-77%) seroconverted. Children demonstrated 79% (95% CI 69%-86%) and 82% (95% CI 73%-88%) seroconversion after primary and boosting regimens, respectively. CONCLUSIONS/SIGNIFICANCE:Administration of an OCV boosting regimen elicits an immune response similar to those receiving a primary series in endemic areas. Though a single boosting dose induces a strong immune response, further investigations are needed to measure if these findings translate to clinical protection

Association of physician’s characteristics and knowledge regarding diarrhea with rationality of antibiotic use for diarrheal management (N^a = 264).

<p>Association of physician’s characteristics and knowledge regarding diarrhea with rationality of antibiotic use for diarrheal management (N<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0123479#t002fn002" target="_blank">^a</a> = 264).</p

Distribution of the characteristics and diarrheal management practices among participating physicians (N = 264^a).

<p>Distribution of the characteristics and diarrheal management practices among participating physicians (N = 264<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0123479#t001fn001" target="_blank">^a</a>).</p

Association of physician’s characteristics and knowledge regarding diarrhea with rationality of fluid management and laboratory testing practices while treating diarrhea cases (N^a = 264).

<p>Association of physician’s characteristics and knowledge regarding diarrhea with rationality of fluid management and laboratory testing practices while treating diarrhea cases (N<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0123479#t003fn001" target="_blank">^a</a> = 264).</p

Temporal distribution of <i>S.</i> Typhi haplotypes.

<p>Monthly frequency of <i>S.</i> Typhi coloured by haplotype (haplotypes defined in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001490#pntd-0001490-g001" target="_blank">Figure 1</a>). Vaccines were administered in December 2004 (indicated by arrows) to approximately two thirds of the study population. (A) <i>S.</i> Typhi isolated from typhoid fever patients in geographical clusters assigned to Vi vaccine. (B) <i>S.</i> Typhi isolated from typhoid fever patients in geographical clusters assigned to hepatitis A vaccine.</p